Screening of severe adverse drug reaction by electronic medical record search

Cheol-Woo Kim

doi:10.4168/aard.2018.6.3.135

Journal List > Allergy Asthma Respir Dis > v.6(3) > 1095004

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim: Screening of severe adverse drug reaction by electronic medical record search

Editorial

Allergy, Asthma & Respiratory Disease 2018; 6(3): 135-136.

Published online: 31 May 2018

DOI: https://doi.org/10.4168/aard.2018.6.3.135

Screening of severe adverse drug reaction by electronic medical record search

Cheol-Woo Kim

Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.

Correspondence to: Cheol-Woo Kim. Department of Internal Medicine, Inha University School of Medicine, 27 Inhang-ro, Jung-gu, Incheon 22332, Korea. Tel: +82-32-890-3495, Fax: +82-32-882-6578, cwkim1805@inha.ac.kr

Received 23 April 2018 Revised 9 May 2018 Accepted 9 May 2018

The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

References

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200–1205.

2. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015; 38:437–453.

3. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital--their severity and cost involved. Pharmacoepidemiol Drug Saf. 2003; 12:687–692.

4. Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol. 2004; 18:275–280.

5. Han J, Ye YM, Lee S. Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea. Int J Clin Pharm. 2018 Apr 2. DOI: 10.1007/s11096-018-0625-9. [Epub].

6. Kang DY, Ahn KM, Kang HR, Cho SH. Past, present, and future of pharmacovigilance in Korea. Asia Pac Allergy. 2017; 7:173–178.

7. Yun IS, Koo MJ, Park EH, Kim SE, Lee JH, Park JW, et al. A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital. Korean J Intern Med. 2012; 27:443–450.

8. Yang MS, Jung JW, Kang HR. Severe cutaneous adverse reaction. Korean J Med. 2014; 87:665–674.

9. Seong JM, Park BJ. Recent advance in pharmacovigilance activities of World Health Organization and U.S. Food and Drug Administration. Korean Public Health Res. 2015; 41:19–28.

10. Kang DY, Jang DY, Sohn KH, Kang SY, Kim JY, Cho SH, et al. Optimal methods to detect DRESS (drug reaction with eosinophilia and systemic symptom) syndrome by electronic medical records. Asthma Allergy Respir Dis. 2018; 6:149–154.

TOOLS

ORCID iDs: Cheol-Woo Kim
https://orcid.org/0000-0003-4306-1367
Similar articles